Clinical effects of defibrinogenating enzymes in the treatment of thromboembolism diseases        LI Xiao-xi.Department of Vascular-thyroid-breast Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
Abstract    Antithrombotic therapy plays an important role in the treatment of thromboembolism diseases, such as peripheral arterial disease, deep vein thrombosis and acute ischemic stroke. Plasma fibrinogen is known to play an important role in the pathogenesis of venous and arterial thromboembolism, and is one of the main determinants of blood viscosity. Defibrinogenating enzyme, purified fraction derived from the venom, does not directly affect any other coagulation factors or hematological components.  Defibrinogenation agents reduce rapid fibrinogen concentrations, produces anticoagulation by depleting the substrate needed for thrombus formation. Depletion of fibrinogen also decreases blood viscosity, resulting in improved blood circulation.